{"disease":{"id":"t-cell-lymphomas","name":"t cell lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07160023","title":"Local Registry of Primary Cutaneous T-cell Lymphomas","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03922724","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02362035","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Acerta Pharma BV","has_results":true},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT06561425","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Galapagos NV","has_results":false},{"nct_id":"NCT02520908","title":"Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06035497","title":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06028373","title":"A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Antengene Biologics Limited","has_results":false},{"nct_id":"NCT02030834","title":"Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT06176027","title":"Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Navy General Hospital, Beijing","has_results":false},{"nct_id":"NCT02205333","title":"A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT07279584","title":"Golidocitinib Combined With GemOx in RR PTCL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06647329","title":"CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Mingzhi Zhang","has_results":false},{"nct_id":"NCT05583149","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Patrick C. Johnson, MD","has_results":true},{"nct_id":"NCT01474681","title":"Safety and Tolerability of HSC835 in Patients With Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02341014","title":"Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT06478381","title":"L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03576807","title":"The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Xin Wang","has_results":false},{"nct_id":"NCT06986434","title":"CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT04450069","title":"CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT04488354","title":"Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT05105412","title":"Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT05589896","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Ossium Health, Inc.","has_results":false},{"nct_id":"NCT01744912","title":"Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02271945","title":"Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT02846935","title":"p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Yogen Saunthararajah","has_results":false},{"nct_id":"NCT01579318","title":"Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OncoSec Medical Incorporated","has_results":true},{"nct_id":"NCT04021082","title":"CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)","phase":"PHASE2, PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Portola Pharmaceuticals","has_results":false},{"nct_id":"NCT03617224","title":"Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}